CA3170456A1 - Combination of an lsd-1 inhibitor and nivolumab for use in treating sclc or sqnsclc - Google Patents
Combination of an lsd-1 inhibitor and nivolumab for use in treating sclc or sqnsclc Download PDFInfo
- Publication number
- CA3170456A1 CA3170456A1 CA3170456A CA3170456A CA3170456A1 CA 3170456 A1 CA3170456 A1 CA 3170456A1 CA 3170456 A CA3170456 A CA 3170456A CA 3170456 A CA3170456 A CA 3170456A CA 3170456 A1 CA3170456 A1 CA 3170456A1
- Authority
- CA
- Canada
- Prior art keywords
- weeks
- administered
- lsd
- inhibitor
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062986541P | 2020-03-06 | 2020-03-06 | |
| US62/986,541 | 2020-03-06 | ||
| PCT/US2021/021101 WO2021178807A1 (en) | 2020-03-06 | 2021-03-05 | Combination of an lsd-1 inhibitor and nivolumab for use in treating sclc or sqnsclc |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3170456A1 true CA3170456A1 (en) | 2021-09-10 |
Family
ID=77614361
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3170456A Pending CA3170456A1 (en) | 2020-03-06 | 2021-03-05 | Combination of an lsd-1 inhibitor and nivolumab for use in treating sclc or sqnsclc |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230089536A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4114398A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023516745A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220151637A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115484958A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021230575A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022017637A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3170456A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL296564A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022010912A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021178807A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018276611B2 (en) | 2017-05-31 | 2022-01-06 | Taiho Pharmaceutical Co., Ltd. | Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 |
| MX2022005811A (es) | 2019-11-13 | 2022-06-08 | Taiho Pharmaceutical Co Ltd | Sal novedosa de compuesto de terfenilo. |
| TW202329934A (zh) * | 2021-09-30 | 2023-08-01 | 日商大鵬藥品工業股份有限公司 | 使用聯苯化合物及免疫檢查點分子調節劑之用於癌症的組合療法 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| EP3279215B1 (en) | 2009-11-24 | 2020-02-12 | MedImmune Limited | Targeted binding agents against b7-h1 |
| CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
| BR112014012819B1 (pt) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
| US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| US9175082B2 (en) | 2012-05-31 | 2015-11-03 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-L1 |
| RS61400B1 (sr) | 2013-05-02 | 2021-02-26 | Anaptysbio Inc | Antitela usmerena protiv programirane smrti-1 (pd-1) |
| CA3175360C (en) | 2013-05-31 | 2024-05-28 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-1 |
| SMT202300039T1 (it) | 2013-09-13 | 2023-03-17 | Beigene Switzerland Gmbh | Anticorpi anti-pd1 e loro uso come terapia e per diagnostica |
| CR20160319A (es) | 2013-12-12 | 2016-11-08 | Jiangsu Hengrui Medicine Co | Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對pd-1的人類抗體 |
| UA122479C2 (uk) | 2014-01-24 | 2020-11-25 | Дана-Фарбер Кенсер Інстітьют, Інк. | Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1) |
| WO2015168466A1 (en) | 2014-05-01 | 2015-11-05 | Quanticel Pharmaceuticals, Inc. | Inhibitors of lysine specific demethylase-1 |
| MA42971A (fr) | 2015-03-13 | 2018-08-15 | Cytomx Therapeutics Inc | Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation |
| PE20231958A1 (es) | 2015-07-30 | 2023-12-06 | Macrogenics Inc | Moleculas de union a pd-1 y metodos de uso de las mismas |
| WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
| JP6869987B2 (ja) | 2015-09-01 | 2021-05-12 | アジェナス インコーポレイテッド | 抗pd−1抗体及びその使用方法 |
| EP3402255B1 (en) | 2016-02-02 | 2021-03-31 | Huawei Technologies Co., Ltd. | Emission power verification method, user equipment, and base station |
| WO2017132827A1 (en) | 2016-02-02 | 2017-08-10 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| WO2019075327A1 (en) * | 2017-10-12 | 2019-04-18 | Dana-Farber Cancer Institute, Inc. | TREATMENT OF MERKEL CELL CARCINOMA |
| US11685782B2 (en) * | 2017-10-23 | 2023-06-27 | Children's Medical Center Corporation | Methods of treating cancer using LSD1 inhibitors in combination with immunotherapy |
| AU2018377852B2 (en) * | 2017-11-29 | 2022-03-24 | Epiaxis Therapeutics Pty Ltd | Enhancing T-cell function and treating a T-cell dysfunctional disorder with a combination of an LSD inhibitor and a PD1 binding antagonist |
| CA3143030A1 (en) * | 2019-06-13 | 2020-12-17 | Celgene Corporation | Methods of treating cancer by targeting cold tumors |
-
2021
- 2021-03-05 BR BR112022017637A patent/BR112022017637A2/pt not_active Application Discontinuation
- 2021-03-05 US US17/909,292 patent/US20230089536A1/en not_active Abandoned
- 2021-03-05 CN CN202180030907.0A patent/CN115484958A/zh active Pending
- 2021-03-05 MX MX2022010912A patent/MX2022010912A/es unknown
- 2021-03-05 KR KR1020227034176A patent/KR20220151637A/ko not_active Ceased
- 2021-03-05 WO PCT/US2021/021101 patent/WO2021178807A1/en not_active Ceased
- 2021-03-05 IL IL296564A patent/IL296564A/en unknown
- 2021-03-05 AU AU2021230575A patent/AU2021230575A1/en not_active Abandoned
- 2021-03-05 EP EP21714748.7A patent/EP4114398A1/en not_active Withdrawn
- 2021-03-05 JP JP2022553181A patent/JP2023516745A/ja active Pending
- 2021-03-05 CA CA3170456A patent/CA3170456A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2022010912A (es) | 2022-11-09 |
| EP4114398A1 (en) | 2023-01-11 |
| CN115484958A (zh) | 2022-12-16 |
| JP2023516745A (ja) | 2023-04-20 |
| BR112022017637A2 (pt) | 2022-11-08 |
| US20230089536A1 (en) | 2023-03-23 |
| KR20220151637A (ko) | 2022-11-15 |
| WO2021178807A1 (en) | 2021-09-10 |
| IL296564A (en) | 2022-11-01 |
| AU2021230575A1 (en) | 2022-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7653398B2 (ja) | 癌を処置するためのグルタミン酸調節剤と免疫療法の併用 | |
| Md Yusof et al. | Targeting interleukin-6 in rheumatoid arthritis | |
| Behrens et al. | MOR103, a human monoclonal antibody to granulocyte–macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial | |
| Takeuchi et al. | Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study through 24 weeks | |
| Taylor et al. | Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial | |
| Deeks | Certolizumab pegol: a review in inflammatory autoimmune diseases | |
| TWI912619B (zh) | 使用抗pd-1抗體與抗ctla-4抗體之組合以治療肺癌 | |
| US20230089536A1 (en) | Combination of an lsd-1 inhibitor and nivolumab for use in treating sclc or sqnsclc | |
| EP3551663A1 (en) | Methods of treating cancer using anti-pd-l1 antibodies and antiandrogens | |
| US20200277387A1 (en) | Methods and compositions for treating cancer | |
| IL272418B2 (en) | Abinotuzumab treatment of a new subgroup of DLBCL patients | |
| JP2022527334A (ja) | 腫瘍を処置するための抗cd73、抗pd-l1抗体及び化学療法 | |
| CN113677402A (zh) | 治疗肿瘤的方法 | |
| TW202541838A (zh) | 抗cd38抗體在治療新診斷的多發性骨髓瘤中之用途 | |
| TW202535462A (zh) | 在ctdna高風險患者中的抗cd20/抗cd3雙特異性抗體與化學療法之組合治療 | |
| CN112915202B (zh) | 喹啉衍生物与pd-1单抗的药物组合 | |
| US20220073622A1 (en) | Compositions and Methods for Treating Late Stage Lung Cancer | |
| WO2020250033A1 (en) | Combination therapies using cd-38 antibodies | |
| US20130267484A1 (en) | Treatment of rheumatoid arthritis with masitinib | |
| JP2024144605A (ja) | がんを処置するための方法および組成物 | |
| Ozer et al. | Clinical efficacy of TNF-[alpha] inhibitors: an update | |
| JP2021523879A (ja) | 後期肺癌の処置のための組成物及び方法 | |
| Borówka et al. | Adverse Renal Effects of Anticancer Immunother-apy: A Review. Cancers 2022, 14, 4086 | |
| JP2023538683A (ja) | 鼻咽頭癌の治療における抗pd-1抗体の使用 | |
| Sieper | Full Length Arthritis & Rheumatology |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250826 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20251027 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260202 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B301 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO A REQUEST FOR EXAMINATION NOTICE Effective date: 20260402 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260416 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260703 |